{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 448013724
| IUPAC_name = ''N''-[(7''S'')-3-(β-<small>D</small>-Glucopyranosyloxy)-1,2-dimethoxy-10-(methylsulfanyl)-9-oxo-5,6,7,9-tetrahydrobenzo[''a'']heptalen-7-yl]ethanamide
| image = Thiocolchicoside.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|thiocolchicoside}}
| legal_status = Rx-only
| routes_of_administration = [[oral administration|Oral]], [[Topical]], [[Intramuscular|IM]]

<!--Pharmacokinetic data-->
| bioavailability = 25%<ref name="pmid8983937">{{cite journal |vauthors=Perucca E, Poitou P, Pifferi G | title = Comparative pharmacokinetics and bioavailability of two oral formulations of thiocolchicoside, a GABA-mimetic muscle relaxant drug, in normal volunteers | journal = European Journal of Drug Metabolism and Pharmacokinetics | volume = 20 | issue = 4 | pages = 301–5 | year = 1995 | pmid = 8983937 | doi = 10.1007/bf03190249| url = }}</ref>
| elimination_half-life = 5-6 hours<ref name="pmid8983937"/><ref name="pmid8161719">{{cite journal |vauthors=Sandouk P, Bouvier d'Yvoire M, Chretien P, Tillement JP, Scherrmann JM | title = Single-dose bioavailability of oral and intramuscular thiocolchicoside in healthy volunteers | journal = Biopharmaceutics & Drug Disposition | volume = 15 | issue = 1 | pages = 87–92 |date=January 1994 | pmid = 8161719 | doi = 10.1002/bdd.2510150108| url = }}</ref>

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 602-41-5
| ATC_prefix = M03
| ATC_suffix = BX05
| PubChem = 72067
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1705373
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = T1X8S697GT
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07276
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8091534


<!--Chemical data-->
| C=27 | H=33 | N=1 | O=10 | S=1 
| molecular_weight = 563.618 g/mol
| smiles = O=C(N[C@@H]4C1=C\C(=O)C(/SC)=C\C=C1c3c(cc(O[C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)CO)c(OC)c3OC)CC4)C
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C27H33NO10S/c1-12(30)28-16-7-5-13-9-18(37-27-24(34)23(33)22(32)19(11-29)38-27)25(35-2)26(36-3)21(13)14-6-8-20(39-4)17(31)10-15(14)16/h6,8-10,16,19,22-24,27,29,32-34H,5,7,11H2,1-4H3,(H,28,30)/t16-,19+,22+,23-,24+,27+/m0/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = LEQAKWQJCITZNK-AXHKHJLKSA-N
}}

'''Thiocolchicoside''' ('''Muscoril''', '''Myoril''', '''Neoflax''') is a [[muscle relaxant]] with [[anti-inflammatory]] and [[analgesic]] effects.<ref name="pmid14563464">{{cite journal  |vauthors=Tüzün F, Unalan H, Oner N, etal | title = Multicenter, randomized, double-blinded, placebo-controlled trial of thiocolchicoside in acute low back pain | journal = Joint, Bone, Spine : Revue Du Rhumatisme | volume = 70 | issue = 5 | pages = 356–61 |date=September 2003 | pmid = 14563464 | doi = 10.1016/S1297-319X(03)00075-7| url = http://linkinghub.elsevier.com/retrieve/pii/S1297319X03000757}}</ref><ref name="pmid19780000">{{cite journal |vauthors=Ketenci A, Basat H, Esmaeilzadeh S | title = The efficacy of topical thiocolchicoside (Muscoril) in the treatment of acute cervical myofascial pain syndrome: a single-blind, randomized, prospective, phase IV clinical study | journal = Journal of the Turkish Society of Algology | volume = 21 | issue = 3 | pages = 95–103 |date=July 2009 | pmid = 19780000 | doi = | url = http://www.journalagent.com/pubmed/linkout.asp?ISSN=1300-0012&PMID=19780000}}</ref><ref name="pmid18839644">{{cite journal |vauthors=Soonawalla DF, Joshi N | title = Efficacy of thiocolchicoside in Indian patients suffering from low back pain associated with muscle spasm | journal = Journal of the Indian Medical Association | volume = 106 | issue = 5 | pages = 331–5 |date=May 2008 | pmid = 18839644 | doi = | url = }}</ref><ref name="pmid15963201">{{cite journal |vauthors=Ketenci A, Ozcan E, Karamursel S | title = Assessment of efficacy and psychomotor performances of thiocolchicoside and tizanidine in patients with acute low back pain | journal = International Journal of Clinical Practice | volume = 59 | issue = 7 | pages = 764–70 |date=July 2005 | pmid = 15963201 | doi = 10.1111/j.1742-1241.2004.00454.x | url = http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1368-5031&date=2005&volume=59&issue=7&spage=764}}</ref> It acts as a [[competitive inhibition|competitive]] [[GABAA receptor|GABA<sub>A</sub> receptor]] [[receptor antagonist|antagonist]] and also [[glycine receptor antagonist]] with similar [[potency (pharmacology)|potency]] and [[nicotinic acetylcholine receptor]]s to a much lesser extent.<ref name="pmid16806306">{{cite journal  |vauthors=Carta M, Murru L, Botta P, etal | title = The muscle relaxant thiocolchicoside is an agonist of GABAA receptor function in the central nervous system | journal = Neuropharmacology | volume = 51 | issue = 4 | pages = 805–15 |date=September 2006 | pmid = 16806306 | doi = 10.1016/j.neuropharm.2006.05.023 | url = http://linkinghub.elsevier.com/retrieve/pii/S0028-3908(06)00148-1}}</ref><ref name="pmid17234181">{{cite journal  |vauthors=Mascia MP, Bachis E, Obili N, etal | title = Thiocolchicoside inhibits the activity of various subtypes of recombinant GABA(A) receptors expressed in Xenopus laevis oocytes | journal = European Journal of Pharmacology | volume = 558 | issue = 1-3 | pages = 37–42 |date=March 2007 | pmid = 17234181 | doi = 10.1016/j.ejphar.2006.11.076 | url = http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(06)01380-X}}</ref> It has powerful [[convulsant]] activity and should not be used in [[seizure]]-prone individuals.<ref name="pmid11554898">{{cite journal |vauthors=De Riu PL, Rosati G, Sotgiu S, Sechi G | title = Epileptic seizures after treatment with thiocolchicoside | journal = Epilepsia | volume = 42 | issue = 8 | pages = 1084–6 |date=August 2001 | pmid = 11554898 | doi = 10.1046/j.1528-1157.2001.0420081084.x| url = http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0013-9580&date=2001&volume=42&issue=8&spage=1084}}</ref><ref name="pmid19707540">{{cite journal |vauthors=Giavina-Bianchi P, Giavina-Bianchi M, Tanno LK, Ensina LF, Motta AA, Kalil J | title = Epileptic seizure after treatment with thiocolchicoside | journal = Therapeutics and Clinical Risk Management | volume = 5 | issue = 3 | pages = 635–7 |date=June 2009 | pmid = 19707540 | pmc = 2731019 | doi = 10.2147/tcrm.s4823| url = http://www.dovepress.com/articles.php?article_id=3422}}</ref><ref name="pmid12967581">{{cite journal |vauthors=Sechi G, De Riu P, Mameli O, Deiana GA, Cocco GA, Rosati G | title = Focal and secondarily generalised convulsive status epilepticus induced by thiocolchicoside in the rat | journal = Seizure : the Journal of the British Epilepsy Association | volume = 12 | issue = 7 | pages = 508–15 |date=October 2003 | pmid = 12967581 | doi = 10.1016/S1059-1311(03)00053-0| url = http://linkinghub.elsevier.com/retrieve/pii/S1059131103000530}}</ref>

== Side effects ==
Side effect of thiocolchicoside can include nausea, allergy and vasovagal reactions.<ref>{{Cite journal|title = Thiocolchicoside-induced liver injury|date = Mar 2011|pmc=3072020 | pmid=21552685|volume=66|journal=Clinics (Sao Paulo)|pages=521–2|vauthors=Efe C, Purnak T, Ozaslan E, Milanlioglu A|doi=10.1590/s1807-59322011000300029}}</ref>

Although muscle relaxants may have the major side effect of sedation, thiocholchicoside is free from sedation effects possible due to non-interference with nicotinic receptors.{{Citation needed|date = December 2014}}

==Pharmacokinetics==
Thiocolchicoside is broken down in the body to a [[metabolite]] called [[3-demethylthiocolchicine]] (also known as SL59.0955 or M2) that could damage dividing cells therefore inducing toxicity in the embryo, neoplastic changes and fertility reduction in males.{{citation needed|date=November 2013}} Therefore, recommended oral dose should not exceed 7 days and intramuscular dose duration should not exceed 5 days.{{medcn|date=February 2014}}  Local skin preparations are less toxic.

==References==
{{Reflist|2}}

{{Muscle relaxants}}
{{Analgesics}}
{{Anti-inflammatory}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{GABA receptor antagonists}}
{{Glycine receptor antagonists}}
{{Nicotinic acetylcholine receptor modulators}}
}}

[[Category:Glucosides]]
[[Category:Phenol ethers]]
[[Category:Acetamides]]
[[Category:Tropones]]
[[Category:Heptalenes]]
[[Category:Thioethers]]
[[Category:Glycine receptor antagonists]]
[[Category:GABAA receptor antagonists]]
[[Category:Nicotinic antagonists]]